ArticleVirchows Archiv : an international journal of pathology2024

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.

Charo Garrido et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.